Anaphylaxis Treatment Market report offers Market Size, Dynamics, Regional Market Share, Top Key Players, Latest trends, Growth factors, Industry Stats, Historic Market, Business Intelligence, Business Research Reports, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024
Global Anaphylaxis Treatment Market is driven by the increase in the incidence of anaphylaxis around the world. In addition, promising product launches by the major companies such as Teva Pharmaceuticals, Inc. and others, an increase in awareness regarding available treatment options for anaphylaxis among healthcare professionals and patients are boosting the market revenue growth of anaphylaxis treatment market. However, the cost of the treatment, lack of awareness in underdeveloped regions regarding the allergic reaction treatment, and side effects of the drugs used for treatment are hindering the growth of anaphylaxis treatment market.
A sample of this report is available upon request @
Global anaphylaxis treatment market has been segmented based on drug class, route of administration and distribution channel
Based on drug class, anaphylaxis treatment market is segmented into
- Adrenergic Agents (Epinephrine)
- Anti-Histamines
- Others
Based on route of administration, anaphylaxis treatment market is segmented into
- Parenteral
- Oral
- Others
Based on distribution channel, anaphylaxis treatment market is segmented into
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
To view TOC of this report is available upon request @
Global anaphylaxis treatment market is much consolidated in nature due to the presence of very few players in the market. The introduction of the auto-injectors to treat the anaphylaxis revolutionised the anaphylaxis treatment market. Market players are increasing their market presence by collaborations and partnerships. In addition, marketers focusing on the product launches and expanding into other regions for better revenue realization. For instance, in 2015, ALK-Abelló and bioCSL (CSL Limited) entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as GRAZAX in Europe and GRASTEK in North America), and its adrenaline auto-injector, Jext. ALK will be responsible for product supply and bio CLS will undertake registration and commercialisation of the products. Companies reducing the costs by introducing the generic, cheaper versions of the epinephrine auto-injectors to penetrate into the market. For instance, Mylan N.V. has introduced the generic version of EpiPen at half the price. The initial pack of two was sold at US$600 until December 2016 which will be sold at US$ 300 from January 2017.
Geographically Anaphylaxis treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to lead the anaphylaxis treatment market due to increase in the incidence of anaphylaxis, lifestyle changes and raising awareness about available treatment for anaphylaxis among healthcare professionals. Europe anaphylaxis treatment market expected to grow at healthier rate due to increased adoption of the new technologies in the treatment of anaphylaxis. Asia Pacific anaphylaxis treatment market expected to grow at faster rates owing to larger pool patients coupled with high medical unmet need in the region.
Need more information about this report @
Geographically anaphylaxis treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to lead the anaphylaxis treatment market due to increase in incidence of anaphylaxis, lifestyle changes and rising awareness about available treatment for anaphylaxis among healthcare professionals. Europe anaphylaxis treatment market expected to grow at healthier rate due to increased adoption of the new technologies in treatment of anaphylaxis. Asia Pacific anaphylaxis treatment market expected to grow at faster rates owing to larger pool patients coupled with high medical unmet need in the region.
Some of the market players in anaphylaxis treatment market are ALK-Abelló (Denmark), Impax Laboratories Inc. (U.S.), Lincoln Medical Ltd. (New Zealand), Mylan NV ( U.S.), Adamis Pharmaceutical Corporation (U.S.), MannKind Corporation (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline Plc. (U.K) , Merck & Co., Inc. (U.S.) to name a few.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-anaphylaxis-treatment-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com